Scarica l'app Stockscreener
12.48
2.80%
-0.36
Precedente Chiudi:
$12.84
Aprire:
$12.77
Volume 24 ore:
2.36M
Relative Volume:
1.95
Capitalizzazione di mercato:
$665.82M
Reddito:
$1.02B
Utile/perdita netta:
$-757.20M
Rapporto P/E:
-0.8455
EPS:
-14.76
Flusso di cassa netto:
$-257.90M
1 W Prestazione:
+28.13%
1M Prestazione:
+41.50%
6M Prestazione:
+133.71%
1 anno Prestazione:
+37.75%
Intervallo 1D:
$11.62
$13.00
Intervallo di 1 settimana:
$9.21
$13.41
Portata 52W:
$4.02
$13.41
Emergent Biosolutions Inc Stock (EBS) Company Profile
Nome
Emergent Biosolutions Inc
Settore
Telefono
240-631-3200
Indirizzo
300 PROFESSIONAL DR, GAITHERSBURG, MD
Confronta EBS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
12.48 | 676.67M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2024-03-07 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-08-29 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Iniziato | The Benchmark Company | Buy |
| 2021-02-24 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-07-31 | Reiterato | Chardan Capital Markets | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-09-04 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-08-03 | Reiterato | Chardan Capital Markets | Buy |
| 2018-06-13 | Iniziato | Argus | Buy |
| 2018-04-25 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2018-01-16 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | Singular Research | Buy |
| 2016-04-15 | Iniziato | Chardan Capital Markets | Buy |
| 2016-03-28 | Iniziato | Singular Research | Buy |
| 2016-02-19 | Iniziato | Wells Fargo | Outperform |
| 2014-05-15 | Iniziato | Summer Street Research | Buy |
| 2011-05-31 | Reiterato | WBB Securities | Strong Buy |
| 2011-01-10 | Reiterato | Wedbush | Outperform |
| 2010-11-05 | Reiterato | Wedbush | Outperform |
| 2010-08-18 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Reiterato | Caris & Company | Buy |
Mostra tutto
Emergent Biosolutions Inc Borsa (EBS) Ultime notizie
Published on: 2025-11-01 02:24:00 - newser.com
Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out? - sharewise.com
Published on: 2025-10-31 21:41:14 - newser.com
Emergent BioSolutions’ Earnings Call Highlights Strong Growth - The Globe and Mail
Biodefense Market to Attain USD 32.87 Billion by 2034, Driven by Biotech Advancements and Government Funding - GlobeNewswire Inc.
Emergent Biosolutions (NYSE:EBS) Shares Gap Up After Strong Earnings - MarketBeat
Emergent BioSolutions Raises Full-Year Revenue Guidance - MSN
Why Emergent BioSolutions Inc. stock could rally in 20252025 Retail Activity & Real-Time Volume Analysis - newser.com
Reversal indicators forming on Emergent BioSolutions Inc. stock2025 Fundamental Recap & Free Fast Entry Momentum Trade Alerts - newser.com
Why millennials buy Emergent BioSolutions Inc. (ER4) stockJuly 2025 Market Mood & Precise Buy Zone Tips - newser.com
Will Emergent BioSolutions Inc. benefit from macro trendsWeekly Market Report & High Accuracy Investment Signals - newser.com
Is Emergent BioSolutions Inc. stock dividend yield sustainableJuly 2025 PostEarnings & Risk Controlled Stock Pick Alerts - newser.com
Why Emergent BioSolutions Inc. stock remains resilientTrend Reversal & Reliable Entry Point Trade Alerts - newser.com
Analyzing Emergent BioSolutions Inc. with multi timeframe charts2025 Market WrapUp & Expert Approved Trade Ideas - newser.com
What sentiment indicators say about Emergent BioSolutions Inc. stock2025 Volume Leaders & Reliable Entry Point Alerts - newser.com
symbol__ Stock Quote Price and Forecast - CNN
How Emergent BioSolutions Inc. stock benefits from tech adoptionJuly 2025 Momentum & Verified Momentum Watchlists - newser.com
Why Emergent BioSolutions Inc. (ER4) stock is trending on social media2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Emergent BioSolutions Reports Strong Q3 2025 Results - The Globe and Mail
Why Emergent BioSolutions Inc. (ER4) stock is listed among top recommendations2025 Investor Takeaways & Expert Approved Trade Ideas - newser.com
Will breakout in Emergent BioSolutions Inc. lead to full recovery2025 Market Trends & Low Drawdown Trading Techniques - newser.com
Will Emergent BioSolutions Inc. stock return to pre crisis levelsPortfolio Update Report & Stepwise Trade Signal Guides - newser.com
Emergent Biosolutions (NYSE:EBS) Issues Quarterly Earnings Results, Beats Expectations By $1.18 EPS - MarketBeat
Emergent BioSolutions Inc (EBS) Q3 2025 Earnings Call Highlights: Surpassing Revenue ... By GuruFocus - Investing.com Canada
Emergent BioSolutions (EBS) Earnings Transcript - The Globe and Mail
Emergent BioSolutions Inc (EBS) Q3 2025 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Emergent BioSolutions raises 2025 guidance to $835M revenue and $210M EBITDA as international MCM sales surge - MSN
Gaithersburg-based Emergent Biosolutions reports Q3 earnings - Maryland Daily Record
Will Emergent BioSolutions Inc. stock sustain high P E ratiosJuly 2025 Gainers & Precise Buy Zone Identification - newser.com
Why Emergent BioSolutions Inc. (ER4) stock remains top ratedMarket Growth Summary & Verified Entry Point Signals - newser.com
Emergent Biosolutions: Q3 Earnings Snapshot - Stamford Advocate
Understanding Emergent BioSolutions Inc.’s price movementWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
Is Emergent BioSolutions Inc. a candidate for recovery playGlobal Markets & Community Trade Idea Sharing Platform - newser.com
Emergent Biosolutions earnings beat by $1.01, revenue topped estimates - Investing.com Canada
Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates - sharewise.com
EBS Boosts Financial Outlook for Fiscal Year - GuruFocus
Emergent BioSolutions Inc Bottom Line Drops In Q3 - Nasdaq
Emergent BioSolutions Inc Reports Q3 2025 Earnings: EPS of $0.91 - GuruFocus
Emergent BioSolutions Q3 revenue beats guidance, raises full-year outlook - TradingView
Emergent BioSolutions Reports Third Quarter 2025 Financial Results - The Manila Times
How Emergent BioSolutions Inc. (ER4) stock behaves in tightening cyclesJuly 2025 Catalysts & Community Trade Idea Sharing Platform - newser.com
Investors in Emergent BioSolutions (NYSE:EBS) have unfortunately lost 90% over the last five years - Yahoo Finance
Chart based exit strategy for Emergent BioSolutions Inc.Watch List & High Accuracy Investment Entry Signals - newser.com
Emergent Biosolutions Inc Azioni (EBS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.18%
1.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):